Plasma pharmacokinetics and synovial fluid concentrations after oral administration of single and multiple doses of celecoxib in Greyhounds

American Journal of Veterinary Research

Volumn 66, Issue 8, 2005, Pages 1441-1445

  Hunter, Robert P ^a,b   Radlinsky, Mary Ann ^a,c   Koch, David E ^a   Corse, Matthew ^a,d   Pellerin, Marie A ^a   Halstead, Jennifer ^a  

^a KANSAS STATE UNIVERSITY   (United States)

^b ELANCO ANIMAL HEALTH   (United States)

^c UNIVERSITY OF GEORGIA   (United States)

^d Northlake Veterinary Specialists   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; VETERINARY DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; PYRAZOLE DERIVATIVE; SULFONAMIDE;

AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; DOG; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SYNOVIAL FLUID LEVEL; FEMALE; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NONHUMAN; SINGLE DRUG DOSE; ANIMAL; BLOOD; CHEMISTRY; METABOLISM; SYNOVIAL FLUID; TISSUE DISTRIBUTION;

ANIMALIA; CANIS FAMILIARIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AREA UNDER CURVE; DOGS; FEMALE; MALE; PYRAZOLES; SULFONAMIDES; SYNOVIAL FLUID; TISSUE DISTRIBUTION;

EID: 26944451354     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.2005.66.1441     Document Type: Article

References (31)

1. Lankford SM, Bai SA, Goldstein JA. Cloning of canine cytochrome P450 2E1 cDNA: identification and characterization of two variant alleles. Drug Metab Dispos 2000;28:981-986.
2. Paulson SK, Engel L, Reitz B, et al. Evidence for polymorphism in the canine metabolism of the cyclooxygenase 2 inhibitor, celecoxib. Drug Metab Dispos 1999;27:1133-1142.
3. Sagara K, Mizuta H, Ohshiko M, et al. Relationship between the phasic period of interdigestive migrating contraction and the systemic bioavailability of acetaminophen in dogs. Pharm Res 1995;12:594-598.
4. 1-dealkylation and identification of some neutral and phenolic metabolites in canine urine by gas chromatography-mass spectrometry. Xenobiotica 2002;32:809-821.
5. Dumasia MC, Grainger L, Houghton E. Biotransformation of cyclizine in greyhounds. 1: identification and analysis of cyclizine and some basic metabolites in canine urine by gas chromatography-mass spectrometry. Xenobiotica 2002;32:795-807.
6. Sams RA, Muir WW, Detra RL, et al. Comparative pharmacokinetics and anesthetic effects of methohexital, pentobarbital, thiamylal, and thiopental in Greyhound dogs and non-Greyhound, mixed-breed dogs. Am J Vet Res 1985;46:1677-1683.
7. Gough A, Thomas A. Breed predispositions to disease in dogs & cats. Oxford: Blackwell Publishing, 2004;86-88.
8. Court MH, Hay-Kraus BL, Hill DW, et al. Propofol hydroxylation by dog liver microsomes: assay development and dog breed differences. Drug Metab Dispos 1999;27:1293-1299.
9. Hay Kraus BL, Greenblatt DJ, Venkatakrishnan K, et al. Evidence for propofol hydroxylation by cytochrome P4502B11 in canine liver microsomes: breed and gender differences. Xenobiotica 2000;30:575-588.
10. Dalvi RR, Nunn VA, Juskevich J. Hepatic cytochrome P-450 dependent drug metabolizing activity in rats, rabbits and several food producing species. J Vet Pharmacol Ther 1987;10:164-168.
11. Lewis DFV, Lake BG. Species differences in coumarin metabolism: a molecular modeling evaluation of CYP2A interactions. Xenobiotica 2002;32:547-561.
12. Kararli TT. Gastrointestinal absorption of drugs. Crit Rev Ther Drug Carrier Syst 1989;6:39-86.
13. Sallovitz J, Lifschitz A, Imperiale F, et al. Breed differences on the plasma availability of moxidectin administered pour-on to calves. Vet J 2002;164:47-53.
14. Short CR, Flory W, Hsieh LC, et al. The oxidative metabolism of fenbendazole: a comparative study. J Vet Pharmacol Ther 1988;11:50-55.
15. Beale BS. Arthropathies. In: Bloomberg MS, Dee JF, Taylor RA, et al, eds. Canine sports medicine and surgery. Philadelphia: WB Saunders Co, 1998;210-222.
16. Rodkey WG, McIlwarith CW, Steadman JR. What's new on the horizon for comparative orthopedic sports medicine. In: Bloomberg MS, Dee JF, Taylor RA, et al, eds. Canine sports medicine and surgery. Philadelphia: WB Saunders Co, 1998;443-447.
17. Tang C, Shou M, Rushmore TH, et al. In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics. Pharmacogenetics 2001;11:223-235.
18. Paulson SK, Vaughn MB, Jessen SM, et al. Pharmacokinetics of celecoxib after oral administration in dogs and humans: effect of food and site of absorption. J Pharmacol Exp Ther 2001;297:638-645.
19. Paulson SK, Zhang JY, Jessen SM, et al. Comparison of celecoxib metabolism and excretion in mouse, rabbit, dog, cynomolgus monkey and rhesus monkey. Xenobiotica 2000;30:731-744.
20. Wigness BD, Dorman FD, Robinson HJ Jr, et al. Catheter with an anchoring tip for chronic joint capsule perfusion. ASAIO Trans 1991;37:M290-M292.
21. Gibaldi M, Perrier P. Pharmacokinetics. 2nd ed. New York: Marcel Dekker Inc, 1982;409-417.
22. Riviere JE. Comparative pharmacokinetics: principles, techniques, and applications. Ames, Iowa: Iowa State University Press, 1999;148-167.
23. Rose MJ, Woolf EF, Matuszewski BK. Determination of celecoxib in human plasma by normal-phase high-performance liquid chromatography with column switching and ultraviolet absorbance detection. J Chromatogr B Biomed Sci Appl 2000;738:377-385.
24. Werner U, Werner D, Pahl A, et al. Investigation of the pharmacokinetics of celecoxib by liquid chromatography-mass spectrometry. Biomed Chromatogr 2002;16:56-60.
25. Daniel WW. Applied nonparametric statistics. Boston: PWS-Kent Publishing Co, 1990;144-177.
26. Ayrton A, Morgan P. Role of transport proteins in drug absorbtion, distribution and excretion. Xenobiotica 2001;31:469-497.
27. Werner U, Werner D, Rau T, et al. Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans. Clin Pharmacol Ther 2003;74:130-137.
28. Nakata H, Sagami F, Horie T. Auto-induction of E5110 metabolism, a novel non-steroidal anti-inflammatory drug, during toxicokinetic studies in Beagle dogs. J Toxicol Sci 2000;25:1-10.
29. Johnson KA, Hart RC, Chu Q, et al. Concentrations of chondroitin sulfate epitopes 3B3 and 7D4 in synovial fluid after intra-articular and extracapsular reconstruction of the cranial cruciate ligament in dogs. Am J Vet Res 2001;62:581-587.
30. Spreng D, Sigrist N, Schweighauser A, et al. Endogenous nitric oxide production in canine osteoarthritis: detection in urine, serum, and synovial fluid specimens. Vet Surg 2001;30:191-199.
31. Day RO, McLachlan AJ, Grahman GC, et al. Pharmacokinetics of nonsteroidal anti-inflammatory drugs in synovial fluid. Clin Pharmacokinet 1999;36:191-210.